Medical Care Technologies (MDCE) AI Stock Analysis

17 Followers

Medical Care Technologies

(Other OTC:MDCE)

Select Model

Rating:60Neutral

Action:reiterated

Date:08/21/26

MDCE scores in the middling range. Financial performance dominates the result: the company carries essentially no debt and has swung to strong reported margins and roughly 25% return on equity, but revenue is minuscule and highly unstable, and profits are not converting into cash — the single biggest risk to the story. Valuation is supportive on paper, with a P/E near 1.0, though such an extreme discount signals market doubt about earnings sustainability and there is no dividend to cushion returns. Technicals cannot be assessed as no trend or momentum indicators were supplied, and the very low beta reflects thin trading rather than defensive quality. Earnings call and corporate event components were excluded for lack of data, with their weight redistributed to the remaining factors.

Positive Factors

Strong ProfitabilityVery high gross and net margins indicate strong current earnings power and potentially favorable economics. If maintained, this profitability can support reinvestment and resilience, although sustaining it depends on stabilizing the revenue base.

Negative Factors

Revenue Contraction and VolatilityA shrinking and inconsistent top line raises questions about demand, customer retention, and the durability of current margins. Without renewed revenue growth, future earnings may be difficult to sustain even if present profitability remains strong.

Medical Care Technologies Business Overview & Revenue Model

Company Description

Medical Care Technologies, Inc. engages in the operation of an online auction house that provides an online platform for memorabilia collectors and professional athletes to consign and sell high valued collectibles in a secure online auction format....

How the Company Makes Money

null

Medical Care Technologies Financial Statement Overview

Summary

A debt-free, equity-funded balance sheet (debt-to-equity near 0.02, equity funding ~97% of assets) is the clear strength, supported by a sharp profitability turnaround — gross margin near 78% and net margin around 46% on a trailing-twelve-month basis, with return on equity around 25% after deep 2023 losses. Offsetting this, revenue is tiny and highly erratic (a 79% collapse in 2023, a rebound in 2025, then a ~9% decline over the trailing twelve months), and cash conversion is weak, with operating cash flow covering less than a fifth of reported net income after an outright cash burn in 2024. The result is a strong balance sheet paired with low-visibility earnings quality.

Income Statement

58Neutral

Balance Sheet

78Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	951.09K	1.07M	656.40K	731.97K	3.47M
Gross Profit	745.82K	576.12K	321.85K	-57.24K	1.33M
EBITDA	439.60K	238.06K	152.99K	0	1.33M
Net Income	434.54K	230.77K	150.38K	-387.51K	1.10M
Balance Sheet
Total Assets	1.91M	1.89M	1.47M	603.46K	1.05M
Cash, Cash Equivalents and Short-Term Investments	363.80K	490.55K	52.34K	35.39K	11.80K
Total Debt	37.78K	10.00K	67.67K	39.14K	27.94K
Total Liabilities	48.52K	26.68K	82.03K	69.48K	124.01K
Stockholders Equity	1.86M	1.86M	1.38M	533.98K	921.49K
Cash Flow
Free Cash Flow	77.93K	155.47K	-616.08K	29.91K	139.55K
Operating Cash Flow	77.93K	155.47K	-616.08K	29.91K	139.55K
Investing Cash Flow	0	0	0	0	0
Financing Cash Flow	-72.37K	70.13K	633.03K	-6,321	-127.75K

Medical Care Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

MDCE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KEQU	62Neutral	$96.72M	12.29	11.34%	―	5.33%	-33.32%
Sector *	61Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
MDCE	60Neutral	―	1.00	24.86%	―	-5.74%	―
MED	47Neutral	$146.83M	-3.49	-21.13%	―	-30.28%	-16409.29%
LAKE	45Neutral	$93.50M	-3.40	-20.59%	1.29%	-0.35%	2.69%
MRM	44Neutral	$2.19M	-0.58	-68.38%	―	―	―
NHTC	39Underperform	$6.81M	-5.25	-8.13%	82.08%	-16.53%	-1330.39%

* Consumer Cyclical Sector Average

Performance Comparison

MDCE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KEQU	Kewaunee Scientific	35.70	-3.82	-9.67%
LAKE	Lakeland Industries, Inc.	9.16	-5.43	-37.22%
MED	Medifast	12.97	1.87	16.85%
NHTC	Natural Health Trends Corp	0.74	-2.69	-78.34%
MRM	Medirom Healthcare Technologies, Inc.	0.28	-1.69	-85.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Medical Care Technologies AI Stock Analysis